Business Wire

Phenom Study: First Benchmark of European 100 Uncovers Opportunities to Meet Job Candidates’ High Expectations

8.6.2022 15:00:00 EEST | Business Wire | Press release

Share

Phenom, the global leader in Talent Experience Management (TXM), released its first-ever State of Candidate Experience Report — European Edition. The comprehensive audit, which assessed the top 100 European companies on the Fortune Global 500 list in three key areas of the talent journey — attraction, engagement and conversion —revealed there is significant room to improve the experience with personalisation and automation.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220608005302/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Inaugural European Edition: State of Candidate Experience Report Provides Recommendations for Improvements (Graphic: Business Wire)

Talent acquisition is now a business priority among the C-suite — especially across industries with high-volume hiring needs — such as healthcare, hospitality, manufacturing, retail and transportation. But instead of using personalisation and automation technology to effectively and efficiently scale hiring, the majority of European 100 companies are falling short.

The 2022 audit of European 100 career sites reveals:

  • Only 9% had an intuitive job search and application process
  • Only 10% sent applicants a satisfaction survey
  • Only 6% had a recruitment chatbot
  • 96% did not present job recommendations based on browsing history
  • 90% did not display recently viewed jobs
  • 68% lacked a job cart or favorites function to save jobs
  • 0% communicated application status beyond initial confirmation

How Companies Can Improve the Candidate Experience

Simplify search and apply. Requiring three or more clicks to apply for a job is a major roadblock for candidates. The longer it takes for a candidate to find and apply to a relevant job, the greater the chance they will abandon the process and look elsewhere. One recommendation is for companies to equip their career sites with the ability to provide relevant suggested jobs based on a candidate’s keywords, skills, experience and location.

Create hyper-personalisation. Candidates are used to superior tailored experiences in their consumer lives. If finding a job that matches what they want is difficult, they are quick to move on. Dynamic personalisation is one way companies can automatically match a candidate’s preferences, experience, skills and location with best-fit job openings — and surface content for candidates as they move through their own unique end-to-end talent journey across multiple channels.

Automate communication. Job seekers want to know where they stand in the screening and interview scheduling process. Failure to communicate status details jeopardises employer brand and acceptance rates. Using conversational AI chatbots, SMS and email campaigns are a few ways companies can automate individualised communications to keep job seekers engaged while differentiating their brand.

“Hiring, developing and retaining talent isn’t just an HR priority — it is a business priority. Companies must differentiate themselves by the experiences they provide to their candidates and their employees to sustain,” said Mahe Bayireddi, CEO and co-founder of Phenom. “This benchmark report of the European 100 provides industry-specific insights and actionable recommendations for using automation and personalisation to earn and keep top talent.”

How Automation Helps Talent Experiences

Automation enables a quick, efficient hiring process that serves up best-fit jobs to candidates — and best-fit candidates to recruiters — while optimising omnichannel communications that nurture talent communities. Not only do job seekers appreciate a streamlined, personalised experience, but with efficiency at the core, recruiters and hiring managers benefit from decreased time to fill and better long-term fits.

Employees are no exception. The same hyper-personalised candidate experience should extend to internal talent, who may be looking to move within their current company. By making relevant open roles and development opportunities visible, actionable and attainable, companies stand a better chance at retaining them. AI-powered talent marketplaces automate the process for an employee experience that unifies all key stakeholders: internal candidates, recruiters and hiring managers.

With this report, companies can learn how to make changes — large or small — to enhance the candidate experience and provide a measurable, positive impact on their businesses.

Download the full 2022 State of the Candidate European Edition report and rankings here. Also recently published, the sixth annual report auditing the Fortune 500 is available for download here. Organisations can request their own complimentary career site audit here.

To request a demo of Phenom TXM visit phenom.com.

About Phenom

Phenom has a purpose of helping a billion people find the right job. Through AI-powered talent experiences, HR teams are using Phenom to hire employees faster, develop them to their full potential, and retain them longer. The Phenom Talent Experience Management (TXM) platform seamlessly connects candidates, employees, recruiters, and managers — empowering over 500 diverse and global enterprises with innovative products including Phenom Career Site, Chatbot, CMS, CRM, AI Scheduling, Video Assessments, Campaigns, University Recruiting, Talent Marketplace, Career Pathing, Gigs, Mentoring, and Referrals.

Phenom was ranked among the fastest-growing technology companies in Deloitte Technology's Fast 500 for four years in a row, has been recognized in Business Intelligence Group's 2021 and 2022 Artificial Intelligence Excellence Awards and won a regional 2020 Timmy Award for launching and optimizing HelpOneBillion.com.

Headquartered in Greater Philadelphia, Phenom also has offices in India, Israel, the Netherlands, Germany and the United Kingdom.

For more information, please visit www.phenom.com. Connect with Phenom on LinkedIn, Twitter, Facebook, YouTube and Instagram.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media
Jannes Zwirner I jannes.zwirner@tonka-pr.com I +49.172.3650385
Julia Trzinski I julia.trzinski@tonka-pr.com I +49.179.6178513

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 11:00:00 EEST | Press release

OM Pharma will reveal preliminary results from the REACH study at the European Academy of Allergy and Clinical Immunology (EAACI) Congress. REACH is the first and largest multi-country real-world evidence (RWE) study to date evaluating the impact of Broncho-Vaxom® in patients with recurrent respiratory tract infections (RTIs).1,2 The findings offer critical new clinical evidence of the therapy's effectiveness in everyday clinical practice. In a real-world cohort of 15,794 paediatric (aged >1 year), adolescent, adult and elderly patients in China, Italy, and Belgium, Broncho-Vaxom® was associated with reductions in RTI recurrence and healthcare utilisation at 12 and 24 months after treatment initiation, compared with the 12 months prior to starting the therapy.1 “The REACH real-world evidence study shows that Broncho-Vaxom® can significantly reduce infections requiring medical visits across age groups and co-morbidities,” said Anna Thomas, Chief Scientific Officer at OM Pharma. “Recurre

Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 18:15:00 EEST | Press release

Incyte (Nasdaq:INCY) today announced updated clinical data from two Phase 1 studies evaluating the safety, tolerability and efficacy of INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, in patients with mutCALR-expressing myeloproliferative neoplasms (MPNs). INCA033989 demonstrated rapid, clinically meaningful responses and consistent molecular activity across both myelofibrosis (MF) and essential thrombocythemia (ET), with convergent evidence supporting the potential for disease modification. These findings are being presented in oral and poster presentations at the European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden (Session: Myeloproliferative neoplasms – Clinical, Presentation numbers: S216, PS1983, PF884). “The data presented at EHA 2026 demonstrate clinically meaningful and consistent responses with INCA033989 across both myelofibrosis and essential thrombocythemia,” said Pablo J. Cagnoni, M.D., President of Incyte and G

Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 13:00:00 EEST | Press release

Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP, the current standard of care, as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. These data are being highlighted in a prestigious Plenary Abstracts Session at the European Hematology Association (EHA) 2026 Congress, being held June 11 - 14, 2026, in Stockholm, Sweden (Abstract # S101. Plenary Abstract Session. June 13, 6:00 - 7:30 a.m. ET [12:00-1:30 p.m. CEST]). frontMIND results were als

Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202613.6.2026 00:31:00 EEST | Press release

Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til

IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 19:36:00 EEST | Press release

IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, strategy, and business transformation. She most recently served as Global Head of Deloitte Digital and previously held senior global leadership roles,

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye